If you are caring for someone with dementia and their doctor has mentioned Auvelity, the drug interaction questions are not academic — they are the first thing a prescriber will check. Auvelity, a combination of dextromethorphan and bupropion, was approved by the FDA on April 30, 2026 for agitation associated with dementia due to Alzheimer’s disease, and its three biggest interaction issues are exactly the ones in this article’s title: it must never be combined with MAOI antidepressants (or taken within 14 days of stopping one), it must not be stacked with other bupropion products like Wellbutrin or Zyban, and it must not be layered on top of over-the-counter cough medicines that contain dextromethorphan. Each of those combinations carries a distinct, serious risk — hypertensive crisis and serotonin syndrome in the first case, seizures in the second, and dextromethorphan toxicity in the third. Consider a common real-world scenario: an 82-year-old with Alzheimer’s disease is already taking bupropion for longstanding depression, and her family gives her Robitussin DM during cold season.
If a neurologist adds Auvelity for her agitation without a full medication review, she is now getting a double dose of bupropion and a double dose of dextromethorphan simultaneously. That is precisely the kind of duplication the FDA label warns about, and it is why the prescribing information directs clinicians to screen for other bupropion- or dextromethorphan-containing products before the first tablet is taken. The good news is that these interactions are well characterized, listed plainly on the FDA label, and manageable with a careful medication reconciliation. The sections below walk through each one — what the risk actually is, why the drug’s unusual pharmacology creates it, and what families and caregivers should ask before starting.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why Do Bupropion and Dextromethorphan Interact With So Many Other Drugs?
- The MAOI Contraindication: The One Absolute Rule
- The Duplication Problem: Wellbutrin, Zyban, and Cough Medicine
- How Auvelity’s Interaction Profile Compares to the Antipsychotic Alternative
- Seizure Risk and Other Threshold-Lowering Drugs
- What “Approved for Dementia” Actually Means Here
- Building a Practical Interaction Checklist Before the First Dose
- Frequently Asked Questions
Why Do Bupropion and Dextromethorphan Interact With So Many Other Drugs?
Auvelity is not a single drug but an extended-release multilayer tablet combining dextromethorphan hydrobromide and bupropion hydrochloride, available in 45 mg/105 mg and, per the 2026 label, 30 mg/105 mg strengths. The two ingredients were paired deliberately: dextromethorphan is the active NMDA-receptor antagonist, but on its own it is broken down so quickly by the liver enzyme CYP2D6 that little reaches the brain. Bupropion inhibits CYP2D6, which boosts and sustains dextromethorphan levels. That clever mechanism is also the root of the drug’s interaction profile — anything else metabolized by CYP2D6, and anything else containing either ingredient, gets amplified. This design first reached the market on August 18, 2022, when Auvelity was approved for major depressive disorder in adults as the first oral NMDA-receptor-antagonist antidepressant.
The interaction warnings on today’s label are largely carried over from that original approval; what changed in 2026 is the patient population. Elderly people with Alzheimer’s disease typically take far more medications than the adults with depression the drug was first studied in, which makes the same interaction list considerably more consequential in practice. A useful comparison: dextromethorphan alone, in a cough syrup, is one of the most widely used over-the-counter ingredients in America and is generally uneventful at labeled doses. Inside Auvelity, with its CYP2D6 escape route blocked by bupropion, the same molecule behaves like a much stronger drug. That is why “it’s just the cough medicine ingredient” is a dangerous way to think about this product.
The MAOI Contraindication: The One Absolute Rule
The strictest interaction on Auvelity’s label involves monoamine oxidase inhibitors — older antidepressants such as phenelzine, tranylcypromine, isocarboxazid, and selegiline. Per the FDA label, Auvelity is contraindicated with MAOIs and within 14 days of stopping one, in either direction: you cannot start Auvelity within 14 days of an MAOI, and you cannot start an MAOI within 14 days of stopping Auvelity. The reason is twofold. Bupropion combined with an MAOI can trigger hypertensive crisis — a sudden, dangerous spike in blood pressure. Dextromethorphan combined with an MAOI can cause serotonin syndrome, a potentially fatal reaction marked by agitation, high fever, rapid heart rate, muscle rigidity, and confusion.
The limitation to understand is that the 14-day washout is not a suggestion or a conservative buffer that a doctor can shorten for convenience. MAOIs bind their target enzyme irreversibly, and the body needs roughly two weeks to manufacture new enzyme. During that window, the interaction risk persists even though the MAOI is no longer being taken. There is a subtle trap here for dementia patients specifically: selegiline, an MAOI, is sometimes prescribed as a transdermal patch (Emsam) for depression or in oral form for Parkinson’s disease, and families do not always think of a patch as an “antidepressant pill.” Linezolid, an antibiotic, and methylene blue, used in certain hospital procedures, also have MAOI activity. A complete medication list — patches, injections, and hospital-administered drugs included — is the only reliable safeguard.
The Duplication Problem: Wellbutrin, Zyban, and Cough Medicine
The second major interaction category is accidental duplication. Bupropion is sold under several names — Wellbutrin for depression, Zyban for smoking cessation, and as a component of some weight-loss combinations — and the fda label requires screening for all of them before starting Auvelity. Stacking bupropion doses raises the risk of seizures and neuropsychiatric side effects, because bupropion’s seizure risk is dose-related. Every Auvelity tablet already contains 105 mg of bupropion; adding a separate 300 mg Wellbutrin prescription on top pushes total daily exposure well beyond what the combination was studied at. Dextromethorphan duplication is the sneakier version of the same problem because it comes from the pharmacy aisle, not the prescription pad.
Products like Delsym, Robitussin DM, Mucinex DM, and NyQuil all contain dextromethorphan, and the “DM” suffix is the tell. Because Auvelity’s bupropion component blocks the enzyme that would normally clear that extra dextromethorphan, over-the-counter doses that would be harmless in most people can accumulate to toxic levels in someone taking Auvelity. A concrete example of how this goes wrong: a caregiver managing a parent’s Alzheimer’s agitation adds a nighttime cold-and-flu liquid during a bout of bronchitis, reasoning that it is sold without a prescription and therefore safe. Within the household’s medication routine, nobody connects the green liquid to the prescription tablet. This is exactly why pharmacists recommend running every over-the-counter purchase past the pharmacy counter once Auvelity is started — the pharmacist’s software will flag the duplication even when the family does not.
How Auvelity’s Interaction Profile Compares to the Antipsychotic Alternative
Before April 2026, the only FDA-approved drug for Alzheimer’s agitation was brexpiprazole (Rexulti), an antipsychotic that carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis. Auvelity’s approval made it the first non-antipsychotic option for this indication, and its label carries no elderly-mortality boxed warning and no falls warning. For families weighing the two, that is a meaningful difference in baseline risk category, even before individual interactions are considered. The tradeoff is that Auvelity brings its own distinct interaction burden that antipsychotics largely do not: the MAOI contraindication, the bupropion seizure issue, and the CYP2D6 inhibition that can raise blood levels of other common drugs metabolized by that enzyme — including some beta-blockers, antidepressants, and antiarrhythmics.
Neither drug is “cleaner” across the board; they simply have different danger zones. A patient with a seizure history tilts the analysis one way; a frail patient at high fall risk may tilt it the other. Long-term data offers some reassurance on the tolerability side: in Axsome’s open-label extension, 456 patients were treated for up to 12 months, with no new safety signals, no increase in falls, sedation, or cognitive decline, and headache as the only adverse event occurring in at least 5% of patients. That falls-and-sedation finding matters specifically because those are the classic liabilities of sedating an agitated elderly person.
Seizure Risk and Other Threshold-Lowering Drugs
Bupropion’s dose-related seizure warning is one of the oldest and best-documented in psychiatry, and it travels with the molecule into Auvelity. The FDA label advises caution when Auvelity is combined with other drugs that lower the seizure threshold. In an elderly dementia population, that list is longer than many families expect: tramadol (a very commonly prescribed painkiller), certain antibiotics such as fluoroquinolones, some antipsychotics, and theophylline all appear on it. Abrupt withdrawal from alcohol or benzodiazepines also lowers the seizure threshold, which is relevant if a patient’s sedative is being tapered at the same time Auvelity is started. The warning here is about circumstances as much as drugs.
Conditions common in late-life illness — severe electrolyte disturbances from dehydration, prior stroke, brain metastases, or a history of head trauma — independently raise seizure risk. A patient who tolerated Auvelity for months can move into a higher-risk situation after a hospitalization adds tramadol for a hip fracture or a fluoroquinolone for pneumonia. Interaction checking is not a one-time event at the first prescription; it has to be repeated at every care transition. It is also worth stating the evidentiary limitation plainly. Of the four randomized double-blind trials supporting the 2026 approval — ADVANCE-1, ADVANCE-2, ACCORD-1, and ACCORD-2 — the ACCORD relapse-prevention studies met their primary endpoint of delaying and preventing agitation relapse, but ADVANCE-2 missed its primary endpoint, with agitation scores on the Cohen-Mansfield Agitation Inventory improving by 13.8 points versus 12.6 points on placebo. The drug is approved and the overall package satisfied the FDA under priority review, but families should not expect a dramatic, unmistakable effect in every patient, and modest benefit shifts the interaction-risk calculus accordingly.
What “Approved for Dementia” Actually Means Here
A precision point that matters for interaction planning: Auvelity is not approved for dementia itself, or for slowing cognitive decline, or for agitation in all dementia types. The April 30, 2026 approval covers agitation associated with dementia due to Alzheimer’s disease specifically.
A patient with Lewy body dementia or vascular dementia who receives Auvelity is being treated off-label, in populations where the trial evidence and the safety data — including how these patients handle the drug’s interactions — is thinner. This distinction has practical consequences. Lewy body dementia patients, for example, are famously sensitive to psychoactive medications generally, and a prescriber considering off-label Auvelity for such a patient should weigh that sensitivity on top of the standard MAOI, duplication, and seizure precautions rather than assuming the Alzheimer’s trial data transfers cleanly.
Building a Practical Interaction Checklist Before the First Dose
The pre-Auvelity medication review has a defined shape, and caregivers can do much of the legwork before the appointment. Gather every prescription bottle, every patch and inhaler, and every over-the-counter product in the house — cough and cold remedies especially — and photograph the labels.
The prescriber or pharmacist will then check three things in order: any MAOI use within the past 14 days (including selegiline patches, linezolid, and methylene blue); any other product containing bupropion (Wellbutrin, Zyban) or dextromethorphan (anything labeled “DM,” Delsym, multi-symptom cold formulas); and any drug that lowers the seizure threshold or is metabolized by CYP2D6. One habit closes most of the remaining gaps: fill every prescription at a single pharmacy so the interaction-screening software sees the complete picture, and ask the pharmacist directly, “Is this safe with Auvelity?” before buying any over-the-counter medicine. The sNDA behind the 2026 approval was submitted November 4, 2025 and reviewed on a priority basis, which means the drug is still new to many community pharmacists in its agitation indication — volunteering that the patient takes it is more reliable than assuming the system will catch everything.
Frequently Asked Questions
Can Auvelity be taken with Wellbutrin or Zyban?
No. Both contain bupropion, the same ingredient already in Auvelity. Combining them raises total bupropion exposure and increases the dose-related risk of seizures and neuropsychiatric side effects.
How long after stopping an MAOI can someone start Auvelity?
At least 14 days, per the FDA label. The same 14-day washout applies in reverse before starting an MAOI after stopping Auvelity. The risks — hypertensive crisis and serotonin syndrome — can be fatal.
Are over-the-counter cough medicines safe with Auvelity?
Products containing dextromethorphan (usually labeled “DM,” plus Delsym and many multi-symptom formulas) are not. Auvelity’s bupropion blocks the enzyme that clears dextromethorphan, so extra doses can accumulate to toxic levels. Ask a pharmacist before buying any cold remedy.
Is Auvelity an antipsychotic?
No. It is the first non-antipsychotic approved for agitation in Alzheimer’s disease. Unlike brexpiprazole (Rexulti), its label carries no boxed warning for elderly mortality and no falls warning.
Does Auvelity treat dementia itself?
No. It is approved specifically for agitation associated with dementia due to Alzheimer’s disease. It does not slow cognitive decline and is not approved for other dementia types.
What side effects showed up in long-term use?
In 456 patients treated up to 12 months, headache was the only adverse event affecting at least 5% of patients, with no observed increase in falls, sedation, or cognitive decline.
